Treatment of Ovarian Hyperstimulation Syndrome in Polycystic Ovary Syndrome Using a GnRH-Agonist Stimulation Protocol
Women with polycystic ovary syndrome (PCOS) who undergo a GnRH-agonist stimulation protocol represent a specific clinical population at elevated consideration for ovarian hyperstimulation syndrome (OHSS). Managing this risk requires a protocol tailored to this scenario.
Clinical Scenario
This protocol applies to patients with
polycystic ovary syndrome who are receiving a GnRH-agonist stimulation protocol — a combination that warrants dedicated attention to OHSS risk.
Treatment Approach (partial)
A specific oral agent is among the options that may be considered to help reduce the risk of OHSS in this setting. The complete structured regimen — including which interventions to use, in what sequence, and under what conditions — is available in the full protocol.
Full regimen details, decision criteria, and clinical guidance are in the protocol below.
References
DOI: 10.1016/j.fertnstert.2023.11.013
Metformin may, however, be considered for OHSS risk reduction among women with PCOS using a GnRH-agonist protocol.
View source ↗